Edmund A Mroz1, James W Rocco. 1. Center for Cancer Research and Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA.
Abstract
OBJECTIVES: Differences among cancer cells within a tumor are important in tumorigenesis and treatment resistance, yet no measure of intratumor heterogeneity is suitable for routine application. We developed a quantitative measure of intratumor genetic heterogeneity, based on differences among mutated loci in the mutant-allele fractions determined by next-generation sequencing (NGS) of tumor DNA. We then evaluated the application of this measure to head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: We analyzed published electronically available NGS results for 74 HNSCC. For each tumor we calculated mutant-allele tumor heterogeneity (MATH) as the ratio of the width to the center of its distribution of mutant-allele fractions among tumor-specific mutated loci. RESULTS: Intratumor heterogeneity assessed by MATH was higher in three poor-outcome classes of HNSCC: tumors with disruptive mutations in the TP53 gene (versus wild-type TP53 or non-disruptive mutations), tumors negative versus positive for human papillomavirus (even when restricted to tumors having wild-type TP53), and HPV-negative tumors from smokers with more pack-years of cigarette exposure (with TP53 status taken into account). CONCLUSION: The relation of this type of intratumor heterogeneity to HNSCC outcome classes supports its further evaluation as a prognostic biomarker. As NGS of tumor DNA becomes widespread in clinical research and practice, MATH should provide a simple, quantitative, and clinically practical biomarker to help evaluate relations of intratumor genetic heterogeneity to outcome in any type of cancer.
OBJECTIVES: Differences among cancer cells within a tumor are important in tumorigenesis and treatment resistance, yet no measure of intratumor heterogeneity is suitable for routine application. We developed a quantitative measure of intratumor genetic heterogeneity, based on differences among mutated loci in the mutant-allele fractions determined by next-generation sequencing (NGS) of tumor DNA. We then evaluated the application of this measure to head and neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: We analyzed published electronically available NGS results for 74 HNSCC. For each tumor we calculated mutant-allele tumor heterogeneity (MATH) as the ratio of the width to the center of its distribution of mutant-allele fractions among tumor-specific mutated loci. RESULTS: Intratumor heterogeneity assessed by MATH was higher in three poor-outcome classes of HNSCC: tumors with disruptive mutations in the TP53 gene (versus wild-type TP53 or non-disruptive mutations), tumors negative versus positive for human papillomavirus (even when restricted to tumors having wild-type TP53), and HPV-negative tumors from smokers with more pack-years of cigarette exposure (with TP53 status taken into account). CONCLUSION: The relation of this type of intratumor heterogeneity to HNSCC outcome classes supports its further evaluation as a prognostic biomarker. As NGS of tumor DNA becomes widespread in clinical research and practice, MATH should provide a simple, quantitative, and clinically practical biomarker to help evaluate relations of intratumor genetic heterogeneity to outcome in any type of cancer.
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Nicolas Stransky; Ann Marie Egloff; Aaron D Tward; Aleksandar D Kostic; Kristian Cibulskis; Andrey Sivachenko; Gregory V Kryukov; Michael S Lawrence; Carrie Sougnez; Aaron McKenna; Erica Shefler; Alex H Ramos; Petar Stojanov; Scott L Carter; Douglas Voet; Maria L Cortés; Daniel Auclair; Michael F Berger; Gordon Saksena; Candace Guiducci; Robert C Onofrio; Melissa Parkin; Marjorie Romkes; Joel L Weissfeld; Raja R Seethala; Lin Wang; Claudia Rangel-Escareño; Juan Carlos Fernandez-Lopez; Alfredo Hidalgo-Miranda; Jorge Melendez-Zajgla; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub; Levi A Garraway; Jennifer R Grandis Journal: Science Date: 2011-07-28 Impact factor: 47.728
Authors: Heath D Skinner; Vlad C Sandulache; Thomas J Ow; Raymond E Meyn; John S Yordy; Beth M Beadle; Alison L Fitzgerald; Uma Giri; K Kian Ang; Jeffrey N Myers Journal: Clin Cancer Res Date: 2011-11-16 Impact factor: 12.531
Authors: Nicholas Navin; Jude Kendall; Jennifer Troge; Peter Andrews; Linda Rodgers; Jeanne McIndoo; Kerry Cook; Asya Stepansky; Dan Levy; Diane Esposito; Lakshmi Muthuswamy; Alex Krasnitz; W Richard McCombie; James Hicks; Michael Wigler Journal: Nature Date: 2011-03-13 Impact factor: 49.962
Authors: Shinichi Yachida; Siân Jones; Ivana Bozic; Tibor Antal; Rebecca Leary; Baojin Fu; Mihoko Kamiyama; Ralph H Hruban; James R Eshleman; Martin A Nowak; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Christine A Iacobuzio-Donahue Journal: Nature Date: 2010-10-28 Impact factor: 49.962
Authors: Cheng Lu; James S Lewis; William D Dupont; W Dale Plummer; Andrew Janowczyk; Anant Madabhushi Journal: Mod Pathol Date: 2017-08-04 Impact factor: 7.842
Authors: Alissa Greenbaum; David R Martin; Thèrése Bocklage; Ji-Hyun Lee; Scott A Ness; Ashwani Rajput Journal: Clin Colorectal Cancer Date: 2019-02-13 Impact factor: 4.481
Authors: Liana Adam; F Anthony San Lucas; Richard Fowler; Yao Yu; Wenhui Wu; Yulun Liu; Huamin Wang; David Menter; Michael T Tetzlaff; Joe Ensor; Ganiraju Manyam; Stefan T Arold; Chad Huff; Scott Kopetz; Paul Scheet; Michael J Overman Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531